Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
BackgroundThe inhibition of the PD-1/PD-L1 axis has exhibited significant advancements in cancer immunotherapy, improving patient outcomes in various cancers. However, the clinical efficacy of these monotherapies remains limited in many cases. Integrin…